Novartis (NYSE:NVS)

160590126

5 Dividend Stocks to Buy as European Index Crushes S&P 500

After years of underperformance, the STOXX Europe 600 is mauling the S&P 500 this year, and it is a trend that could continue for a while. The large European index ...
Read Full Story »
Pills

Analyst’s 8 Top Health Care Stocks for 2015

Health care had an outstanding year in 2014. In fact the sector through last Friday was up 23.30%, which placed it third in the S&P 500 sector race, just behind ...
Read Full Story »
Pills

Is a Generic Diovan for You?

Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to ...
Read Full Story »
DNA

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma Inc. (NASDAQ: ARRY) announced Wednesday after the market close that it had reached a definitive agreement with Novartis A.G. (NYSE: NVS) to regain full worldwide rights to cancer ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AEP, BP, Halliburton, Cypress Semi, J.C. Penney, Schlumberger, SanDisk and More

Stocks were looking for direction Wednesday morning. Investors keep proving that they will buy value stocks or stocks that are discounted when they can. 24/7 Wall St. looks over dozens ...
Read Full Story »
Shell sign at dusk

J.P. Morgan’s 5 Top International Stock Picks

While the U.S. markets have absolutely been on fire, the terminally slow-growth European bourses have been miserable this year for the most part, lagging domestic markets by 22% in U.S. ...
Read Full Story »
Volkswagen Golf 2015

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany’s Volkswagen. The automaker’s 2014 R&D spending will total $13.5 billion, just ahead of ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
DNA

Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher

Binary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

It is Monday and 24/7 Wall St. has seen many new analyst research calls that have to be covered. The bull market is on, with stocks having hit new highs on Friday, but ...
Read Full Story »
down market

Why You Buy Big Pharma If the Market Crashes

Defensive sectors have done well this year, with utilities leading the way. One of the reasons is that despite the market hitting new all-time highs, there remains a wall of ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Avanir, Avon, Broadcom, Endo, Oracle, Wynn and More

Earnings season is in full swing and investors want to make money in upside while avoiding the downside. 24/7 Wall St. reviews dozens of analyst research reports each morning for ...
Read Full Story »
Pills

Akebia, MediWound Post Gains Following IPOs

Mediwound Ltd. (NASDAQ: MDWD) is an Israel-based biopharma firm that is developing, manufacturing and commercializing novel products to address severe burns and other hard-to-heal wounds and connective tissue disorders. The ...
Read Full Story »
biotech

Biotech Buyout Bolsters Novartis Cancer Portfolio

Pharmaceutical giant Novartis A.G. (NYSE: NVS) announced Monday morning that it will acquire startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer ...
Read Full Story »
Pills

Novartis Announces Share Buybacks and Business Expansion

Speculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in London. Instead, on Friday the company announced a $5 billion ...
Read Full Story »